Apogee Therapeutics (APGE) Research & Development (2022 - 2026)
Apogee Therapeutics (APGE) reported Research & Development of $60.8 million for Q1 2026, up 31.11% year-over-year from $46.4 million in Q1 2025, and up 4.06% on a QoQ basis from $58.4 million in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of Research & Development data on file, last reported at $60.8 million in Q1 2026.
- Quarterly Research & Development rose 31.11% year-over-year to $60.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.1 million (up 23.5% YoY) and the FY2025 annual result came in at $214.7 million, up 27.91% from the prior year.
- Research & Development grew to $60.8 million in Q1 2026 per APGE's latest filing, from $58.4 million in the prior quarter.
- Across five years, Research & Development topped out at $60.8 million in Q1 2026 and bottomed at $1.4 million in Q2 2022.
- The 5-year median for Research & Development is $31.1 million (2023), against an average of $33.5 million.
- The widest annual swing landed in 2023, when Research & Development surged 863.12%; it then slipped 2.96% in 2025.
- Tracing APGE's Research & Development over 5 years: stood at $12.2 million in 2022, then surged by 137.17% to $29.0 million in 2023, then soared by 108.02% to $60.2 million in 2024, then fell by 2.96% to $58.4 million in 2025, then rose by 4.06% to $60.8 million in 2026.
- Per Business Quant, the three latest APGE Research & Development figures stand at $60.8 million (Q1 2026), $58.4 million (Q4 2025), and $54.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | 60.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.82 Mn |
| Dec 31, 2025 | 58.44 Mn |
| Sep 30, 2025 | 54.18 Mn |
| Jun 30, 2025 | 55.70 Mn |
| Mar 31, 2025 | 46.39 Mn |
| Dec 31, 2024 | 60.23 Mn |
| Sep 30, 2024 | 45.71 Mn |
| Jun 30, 2024 | 33.21 Mn |
| Mar 31, 2024 | 28.72 Mn |
| Dec 31, 2023 | 28.95 Mn |
| Sep 30, 2023 | 17.07 Mn |
| Jun 30, 2023 | 13.95 Mn |
| Mar 31, 2023 | 8.46 Mn |
| Dec 31, 2022 | 12.21 Mn |
| Sep 30, 2022 | 9.89 Mn |
| Jun 30, 2022 | 1.45 Mn |